User profiles for Emma J. Crosbie

emma j crosbie

Verified email at manchester.ac.uk
Cited by 10127

Human papillomavirus and cervical cancer

EJ Crosbie, MH Einstein, S Franceschi, HC Kitchener - The Lancet, 2013 - thelancet.com
Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus
infection is harmless and clears spontaneously but persistent infection with high-risk human …

Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy

…, H Putter, HC Kitchener, EJ Crosbie… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …

[HTML][HTML] Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

…, I Blanco, K Green, F Lalloo, EJ Crosbie, J Hill… - Genetics in …, 2020 - nature.com
Purpose Pathogenic variants affecting MLH1, MSH2, MSH6, and PMS2 cause Lynch syndrome
and result in different but imprecisely known cancer risks. This study aimed to provide …

[HTML][HTML] Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

…, A Leary, RJ Edmondson, ME Powell, EJ Crosbie… - Modern …, 2015 - nature.com
This study aimed to investigate whether molecular analysis can be used to refine risk
assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial …

Endometrial cancer

EJ Crosbie, SJ Kitson, JN McAlpine, A Mukhopadhyay… - The Lancet, 2022 - thelancet.com
Endometrial cancer is the most common gynaecological cancer in high income countries
and its incidence is rising globally. Although an ageing population and fewer benign …

Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis

EJ Crosbie, M Zwahlen, HC Kitchener, M Egger… - … Biomarkers & Prevention, 2010 - AACR
Background: Body mass index (BMI) is a risk factor for endometrial cancer. We quantified
the risk and investigated whether the association differed by use of hormone replacement …

[HTML][HTML] Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

…, C Genestie, IM Jürgenliemk-Schulz, EJ Crosbie… - British journal of …, 2023 - nature.com
Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological
factors and molecular subgroup. It is unclear whether adding hormone receptor expression, …

[HTML][HTML] The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

EJ Crosbie, NAJ Ryan, MJ Arends, T Bosse, J Burn… - Genetics in …, 2019 - Elsevier
… Author links open overlay panel Emma J. Crosbie PhD 1 2 3 , Neil AJ Ryan MBChB 1 4 ,
Mark J. Arends PhD 5 , Tjalling Bosse PhD 6 , John Burn MD 7 , Joanna M. Cornes BSc 8 , …

Intraoperative interventions for preventing surgical site infection: an overview of Cochrane Reviews

…, J Cawthorne, RP George, EJ Crosbie… - Cochrane Database …, 2018 - cochranelibrary.com
Background Surgical site infection (SSI) rates vary from 1% to 5% in the month following
surgery. Due to the large number of surgical procedures conducted annually, the costs of these …

Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications

…, S Nicholas, AH Balen, EJ Crosbie - Human reproduction …, 2014 - academic.oup.com
BACKGROUND Metformin is an effective oral anti-hyperglycaemic drug used as first-line
medical treatment for type 2 diabetes. It improves systemic hyperglycaemia by reducing hepatic …